Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601835 · ClinicalTrials.gov registry record · Phase 4
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 3,651
- Enrollment target
NCT00601835 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 3,651 participants.
The verdict
NCT00601835, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3,651 participants
- Enrollment target
Study Summary
To compare the seroprotection rates and booster responses to Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the seroprotection rates and booster responses to the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to subjects ≥ 60 years of age. To compare the post-vaccination geometric mean titers of antibody (GMTs) to Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the post-vaccination GMTs to the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to subjects ≥ 60 years of age.
Interventions
- BIOLOGICAL Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,651 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601835
The ClinicalTrials.gov registry entry for NCT00601835 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3,651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine is the first listed.
NCT00601835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601835 about?
NCT00601835 is a clinical study titled "Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td". To compare the seroprotection rates and booster responses to Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the seroprotection rates and booster responses to the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to subjects ≥ 60 years of age....
What is the current status of trial NCT00601835?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3,651 participants. The study started on 2004-05. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00601835?
The interventions under investigation include: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00601835?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.